Ironwood Pharmaceuticals, Inc. (IRWD) Stock Is An 52-Week High Flier

July 12, 2018 - By Ann Prendergast

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Logo

Investors sentiment decreased to 0.7 in Q1 2018. Its down 0.35, from 1.05 in 2017Q4. It worsened, as 20 investors sold Ironwood Pharmaceuticals, Inc. shares while 50 reduced holdings. 19 funds opened positions while 30 raised stakes. 150.40 million shares or 0.28% more from 149.98 million shares in 2017Q4 were reported.
Smith Asset Mngmt Gru Ltd Partnership accumulated 15,380 shares. 15,781 were accumulated by Aperio Llc. Sarissa Mngmt Limited Partnership holds 12.02% or 3.37 million shares. Raymond James Svcs Advsr accumulated 0% or 11,483 shares. Prudential accumulated 14,374 shares or 0% of the stock. Alps Incorporated owns 0.02% invested in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) for 181,590 shares. 245,195 were reported by Citadel Advsr Limited Com. The United Kingdom-based Barclays Public Ltd Co has invested 0% in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD). Tocqueville Asset Mgmt L P invested in 29,612 shares. Employees Retirement Of Ohio holds 108,195 shares or 0.01% of its portfolio. Trexquant Invest Limited Partnership has 0.07% invested in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) for 61,559 shares. Guggenheim Capital Limited Liability Com holds 0.01% of its portfolio in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) for 188,974 shares. Mackay Shields Limited Liability Corp reported 56,269 shares. Penn Mngmt Commerce, a Pennsylvania-based fund reported 849,299 shares. Moreover, Wellington Management Group Inc Limited Liability Partnership has 0.07% invested in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) for 19.13 million shares.

Since January 24, 2018, it had 0 insider purchases, and 11 sales for $2.46 million activity. $26,430 worth of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) was sold by McHugh Julie. $35,240 worth of stock was sold by OLANOFF LAWRENCE S on Tuesday, June 5. Consylman Gina sold $52,688 worth of stock. 29,551 Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) shares with value of $583,632 were sold by Gilbert Halley E. Shares for $23,954 were sold by Currie Mark G.

The stock of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) hit a new 52-week high and has $21.53 target or 7.00 % above today’s $20.12 share price. The 9 months bullish chart indicates low risk for the $3.06B company. The 1-year high was reported on Jul, 12 by Barchart.com. If the $21.53 price target is reached, the company will be worth $213.99M more.
The 52-week high event is an important milestone for every stock because it shows very positive momentum and is time when buyers come in. During such notable technical setup, fundamental investors usually stay away and are careful shorting or selling the stock.

The stock increased 1.11% or $0.22 during the last trading session, reaching $20.12. About 150,338 shares traded. Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) has declined 9.49% since July 12, 2017 and is downtrending. It has underperformed by 22.06% the S&P500.

Analysts await Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) to report earnings on August, 2. They expect $-0.20 earnings per share, up 28.57 % or $0.08 from last year’s $-0.28 per share. After $-0.27 actual earnings per share reported by Ironwood Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts -25.93 % EPS growth.

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Ratings Coverage

Among 5 analysts covering Ironwood Pharma (NASDAQ:IRWD), 3 have Buy rating, 1 Sell and 1 Hold. Therefore 60% are positive. Ironwood Pharma has $2500 highest and $16.0 lowest target. $22.25’s average target is 10.59% above currents $20.12 stock price. Ironwood Pharma had 7 analyst reports since March 12, 2018 according to SRatingsIntel. The rating was upgraded by Mizuho on Wednesday, May 2 to “Buy”. The company was maintained on Monday, March 12 by Mizuho. The stock of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) has “Underweight” rating given on Wednesday, May 9 by Morgan Stanley. The rating was maintained by Wells Fargo with “Outperform” on Thursday, May 31. The rating was maintained by Mizuho with “Buy” on Thursday, May 31. The stock has “Buy” rating by Berenberg on Thursday, April 19.

More recent Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) news were published by: Seekingalpha.com which released: “Ironwood launches late-stage program for IW-3718 in GERD” on June 21, 2018. Also Streetinsider.com published the news titled: “Ironwood Pharma (IRWD) Reports Positive Impact from Praliciguat Phase IIa Study Data on Metabolic a& …” on June 25, 2018. Streetinsider.com‘s news article titled: “Cowen Reiterates Outperform on Ironwood Pharma (IRWD) Following IW-1973 Data” with publication date: June 25, 2018 was also an interesting one.

Ironwood Pharmaceuticals, Inc., a commercial biotechnology company, engages in the research, development, and commercialization of human therapeutic products. The company has market cap of $3.06 billion. The firm markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States and Constella name in the European Union; and lesinurad for the treatment of hyperuricemia associated with uncontrolled gout under ZURAMPIC and DUZALLO names. It currently has negative earnings. It has collaboration agreements with Allergan plc and AstraZeneca AB to develop and commercialize linaclotide for the treatment of IBS-C, CIC, and other GI conditions in North America, China, Hong Kong, and Macau; and license agreement with Astellas Pharma Inc. to develop and commercialize linaclotide for the treatment of IBS-C, chronic constipation, and other GI conditions in Japan.

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: